SpringerLink
Log in

Subtypes of oligodendroglioma defined by 1p,19q deletions, differ in the proportion of apoptotic cells but not in replication-licensed non-proliferating cells

  • Original Paper
  • Published:
Acta Neuropathologica Aims and scope Submit manuscript

Abstract

Oligodendrogliomas may be divided into those with deletion of chromosomes 1p and 19q (Del+), and those without (Del−). Del+ tumours show better survival and chemoresponsiveness but the reason for this difference is unknown. We have investigated whether these subgroups differ in (a) apoptotic index, (b) the proportion of cells licensed for DNA replication but not in-cycle, and (c) the relative length of G1-phase. Fluorescence in situ hybridisation with probes to 1p and 19q was used to determine the deletion status of 54 oligodendrogliomas, including WHO grades II and III. The apoptotic index was determined using counts of apoptotic bodies. Replication-licensed non-proliferating cells were determined from the Mcm2 minus Ki67 labelling index, whilst the geminin to Ki67 ratio was used as a measure of the relative length of G1. Del+ oligodendrogliomas showed a higher apoptotic index than Del− tumours (P = 0.037); this was not accounted for by differences in tumour grade or in proliferation. There were no differences in the Mcm2 − Ki67 index or in the geminin/Ki67 ratio between the subgroups, but grade III tumours showed a higher proportion of licensed non-proliferating cells than grade II tumours (P = 0.001). An increased susceptibility to apoptosis in oligodendrogliomas with 1p ± 19q deletion may be important in their improved clinical outcome compared to Del− tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink F, Souhami L, Laperierre N, Mehta M, Curran W (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J Clin Oncol 24(18):2707–2714

    Article  CAS  PubMed  Google Scholar 

  2. Cairncross J, MacDonald D (1988) Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23:360–364

    Article  CAS  PubMed  Google Scholar 

  3. Cairncross J, MacDonald D (1991) Chemotherapy for oligodendroglioma. Arch Neurol 48:225–227

    CAS  PubMed  Google Scholar 

  4. Cairncross J, Ueki K, Zlatescu M, Lisle D, Finkelstein D, Hammond R, Silver J, Stark P, MacDonald D, Ino Y, Ramsay D, Louis D (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90(19):1473–1479

    Article  CAS  PubMed  Google Scholar 

  5. Duan W, Garner D, Williams S, Funckes-Shippy C, Spath I, Blomme E (2003) Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol 199:221–228

    Article  CAS  PubMed  Google Scholar 

  6. Dudderidge T, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths D, Williams G (2005) Mcm2, Geminin, and Ki67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res 11:2510–2517

    Article  CAS  PubMed  Google Scholar 

  7. Ellis C, Dyson M, Stephenson T, Maltby E (2005) HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol 58:710–714

    Article  CAS  PubMed  Google Scholar 

  8. Ellison D, Steart P, Gatter K, Weller R (1995) Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bcl-2 and p53 proteins. Neuropathol Appl Neurobiol 21:352–361

    CAS  PubMed  Google Scholar 

  9. Endl E, Kausch I, Baack M, Knippers R, Gerdes J, Scholzen T (2001) The expression of Ki-67, MCM3, and p27 defines distinct subsets of proliferating, resting, and differentiated cells. J Pathol 195:457–462

    Article  CAS  PubMed  Google Scholar 

  10. Eward K, Obermann E, Shreeram S, Loddo M, Fanshawe T, Williams C, Jung H, Prevost A, Blow J, Stoeber K, Williams G (2004) DNA replication licensing in somatic and germ cells. J Cell Sci 117:5875–5886

    Article  CAS  PubMed  Google Scholar 

  11. Galderisi U, Cipollaro M, Giordano A (2006) Stem cells and brain cancer. Cell Death Differ 13:5–11

    Article  CAS  PubMed  Google Scholar 

  12. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K, Bursch W, Schulte-Hermann R (1995) In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis and autolytic cell death: a cautionary note. Hepatology 21:1465–1468

    Article  CAS  PubMed  Google Scholar 

  13. Kanner A, Staugitis S, Castilla E, Chernova O, Prayson R, Vogelbaum M, Stevens G, Peereboom D, Suh J, Lee S-Y, Tubbs R, Barnett G (2006) The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. J Neurosurg 104:542–550

    PubMed  Google Scholar 

  14. Kim S, Kim H, Kim T (2005) Clinical, histological, and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors. Acta Neuropathol (Berl) 110:27–38

    Article  CAS  Google Scholar 

  15. Leaver H, Whittle I, Wharton S, Ironside J (1998) Apoptosis in human primary brain tumours. Br J Neurosurg 12:539–546

    Article  CAS  PubMed  Google Scholar 

  16. Li S, Xue W, Khoo U, Ngan H, Chan K, Tam I, Chiu P, Ip P, Tam K, Cheung A (2005) Replicative MCM7 protein as a proliferation marker in endometrial carcinoma: a tissue microarray and clinicopathological analysis. Histopathology 46:307–313

    Article  CAS  PubMed  Google Scholar 

  17. McGarry T, Kirschner M (1998) Geminin, an inhhibitor of DNA replication, is degraded during mitosis. Cell 93:1043–1053

    Article  CAS  PubMed  Google Scholar 

  18. Mollemann M, Wolter M, Felsberg J, Collins V, Reifenberger G (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379–385

    Article  PubMed  CAS  Google Scholar 

  19. Nigro J, Takahashi M, Ginzinger D, Law M, Sandra P, Jenkins R, Aldape K (2001) Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 158:1253–1262

    CAS  PubMed  Google Scholar 

  20. Obermann E, Eward K, Dogan A, Paul E, Loddo M, Munson P, Williams G, Stoeber K (2005) DNA replication licensing in peripheral B-cell lymphoma. J Pathol 205:318–328

    Article  CAS  PubMed  Google Scholar 

  21. Ohgaki H, Kleihues P (2005) Population-based studies in incidence, survival rates and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479–489

    CAS  PubMed  Google Scholar 

  22. Perry A, Fuller C, Banerjee R, Brat D, Scheithauer B (2003) Ancillary FISH analysis for 1p and 19 q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Bioscience 8:a1–a9

    CAS  Google Scholar 

  23. Reifenberger G, Kros J, Burger P, Louis D, Collins V (2000) Oligodendroglioma. In: Kleihues P, Cavenee W (eds) Pathology and Genetics. Tumours of the Nervous System, IARC Press, Lyon, pp 56–64

    Google Scholar 

  24. Reifenberger G, Louis D (2003) Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62:111–126

    CAS  PubMed  Google Scholar 

  25. Reifenberger J, Reifenberger G, Liu L, James C, Wechsler W, Collins V (1994) Molecular genetic analysis of oligodendroglial tumors show preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175–1190

    CAS  PubMed  Google Scholar 

  26. Russo A, Terrasi M, Agnese V, Santini D, Bazan V (2006) Apoptosis: a relevant tool for anticancer therapy. Ann Oncol 17(Suppl 7):vii115–vii123

    Article  PubMed  Google Scholar 

  27. Sasaki H, Zlatescu M, Betensky R, Johnk L, Cutone A, Cairncross J, Louis D (2002) Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade “oligodendroglioma”. J Neuropathol Exp Neurol 61:58–63

    PubMed  Google Scholar 

  28. Schiffer D, Cavalla P, Migheli A, Chio A, Giordana M, Marino S, Attanasio A (1995) Apoptosis and cell proliferation in human neuroepithelial tumors. Neurosci Lett 195:81–84

    Article  CAS  PubMed  Google Scholar 

  29. Schiffer D, Dutto A, Cavalla P, Chio A, Migheli A, Piva R (1997) Role of apoptosis in the prognosis of oligodendrogliomas. Neurochem Int 31:245–250

    Article  CAS  PubMed  Google Scholar 

  30. Schrader C, Janssen D, Klapper W, Siebmann J, Meusers P, Brittinger G, Kneba M, Tiemann M, Parwaresch R (2005) Minichromosome maintenance protein 6, a proliferation marker superior to Ki67 and independent predictor of survival in patients with mantle cell lymphoma. Br J Cancer 93:939–945

    Article  CAS  PubMed  Google Scholar 

  31. Scott I, Morris L, Rushbrook S, Bird K, Vowler S, Burnett N, Coleman N (2005) Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: applications in diagnostic neuropathology. Neuropathol Appl Neurobiol 31:455–466

    Article  PubMed  Google Scholar 

  32. Shetty A, Loddo M, Fanshawe T, Prevost A, Sainsbury R, Williams G, Stoeber K (2005) DNA replication licensing and cell cycle kinetics of normal and neoplastic breast. Br J Cancer 93:1295–1300

    Article  CAS  PubMed  Google Scholar 

  33. Smith J, Alderete B, Minn Y, Borell T, Perry A, Mohapatra G, Hosek S, Kimmel D, O’Fallon J, Yates A, Feuerstein B, Burger P, Scheithauer B, Jenkins R (1999) Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144–4152

    Article  CAS  PubMed  Google Scholar 

  34. Smith J, Perry A, Borell T, Lee H, O’Fallon J, Hosek S, Kimmel D, Yates A, Burger P, Scheithauer B, Jenkins R (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645

    CAS  PubMed  Google Scholar 

  35. Steel G (1977) Basic theory of growing cell populations. In: Steel GG (ed) Growth kinetics of tumours. Clarendon Press, Oxford, pp 56–85

    Google Scholar 

  36. Steinbach J, Weller M (2004) Apoptosis in gliomas: molecular mechanisms and therapeutic implications. J NeuroOncol 70:245–254

    Article  PubMed  Google Scholar 

  37. Stoeber K, Halsall I, Freeman A, Swinn R, Doble A, Morris L, Coleman N, Bullock N, Laskey R, Hales C, Williams G (1999) Immunoassay for urothelial cancers that detects DNA replication protein Mcm5 in urine. Lancet 354:1524–1525

    Article  CAS  PubMed  Google Scholar 

  38. Stoeber K, Tlsty T, Happerfield L, Thomas G, Romanov S, Bobrow L, Williams E, Williams G (2001) DNA replication licensing and human cell proliferation. J Cell Sci 114:2027–2041

    CAS  PubMed  Google Scholar 

  39. Tada S, Li A, Maiorano D, Mechali M, Blow J (2001) Repression of origin assembly in metaphase depends on inhibition of RLF-B/Cdt1 by geminin. Nat Cell Biol 3:107–113

    Article  CAS  PubMed  Google Scholar 

  40. Takeda D, Dutta A (2005) DNA replication and progression through S phase. Oncogene 24:2827–2843

    Article  CAS  PubMed  Google Scholar 

  41. Van Den Bent M, Carpentier A, Brandes A, Sanson M, Taphoorn M, Bernsen H, Frenay M, Tijssen C, Grisold W, Sipos L, Haaxma-Reiche H, Kros J, Van Kouwenhoven M, Vecht C, Allgeier A, Lacombe D, Gorlia T (2006) Adjuvant procarbazine, lomustine and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European organisation for research and treatment of cancer phase III trial. J Clin Oncol 24:2715–2711

    Article  PubMed  CAS  Google Scholar 

  42. Watanabe T, Nakamura M, Kros J, Burkhard C, Yonekawa Y, Kleihues P, Ohgaki H (2002) Phenotype vesus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol 103:267–275

    Article  CAS  PubMed  Google Scholar 

  43. Wharton S, Hamilton F, Chan W, Chan K, Anderson J (1998) Proliferation and cell death in oligodendrogliomas. Neuropathol Appl Neurobiol 24:21–28

    Article  CAS  PubMed  Google Scholar 

  44. Wharton S, Chan K, Anderson J, Stoeber K, Williams G (2001) Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labelling index, histological grade and prognosis. Neuropathol Appl Neurobiol 27:305–313

    Article  CAS  PubMed  Google Scholar 

  45. Wharton S, Hibberd S, Eward K, Crimmins D, Jellinek D, Levy D, Stoeber K, Williams G (2004) DNA replication licensing and cell cycle kinetics of oligodendroglial tumours. Br J Cancer 91:262–269

    CAS  PubMed  Google Scholar 

  46. Williams G, Romanowski P, Morris L, Madine M, Mills A, Stoeber K, Marr J, Laskey R, Coleman N (1998) Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc Natl Acad Sci 95:14932–14937

    Article  CAS  PubMed  Google Scholar 

  47. Williams G, Swinn R, Prevost A, De Clive-Lowe P, Halsall I, Going J, Hales C, Stoeber K, Middleton S (2004) Diagnosis of oesophageal cancer by detection of minichromosome maintenance 5 protein in gastric aspirates. Br J Cancer 91:714–719

    CAS  PubMed  Google Scholar 

  48. Wohlshlegel J, Dwyer B, Dhar S, Cvetic C, Walter J, Dutta A (2000) Inhibition of eukaryotic DNA replication by geminin binding to Cdt1. Science 290:2271–2273

    Google Scholar 

Download references

Acknowledgments

This work received support from the Sheffield Brain Tumour Research Fund and the Evie Clarke Fund.

Author information

Authors and Affiliations

  1. Department of Histopathology, Sheffield Teaching Hospitals, Sheffield, UK

    S. B. Wharton & S. Hibberd

  2. Academic Unit of Pathology, University of Sheffield, Medical School, Beech Hill Road, Sheffield, S10 2RX, UK

    S. B. Wharton

  3. Department of Cytogenetics, Sheffield Children’s Hospital, Sheffield, UK

    E. Maltby & N. Atkey

  4. Department of Neurosurgery, Sheffield Teaching Hospitals, Sheffield, UK

    D. A. Jellinek

  5. Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK

    D. Levy

  6. Department of Paediatric Neurosurgery, Leeds General Infirmary, Leeds, UK

    D. Crimmins

  7. Department of Pathology, Royal Free and University College Medical School, University College London, London, UK

    K. Stoeber & G. H. Williams

Authors
  1. S. B. Wharton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Maltby
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. A. Jellinek
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Atkey
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Hibberd
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Crimmins
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K. Stoeber
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G. H. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. B. Wharton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wharton, S.B., Maltby, E., Jellinek, D.A. et al. Subtypes of oligodendroglioma defined by 1p,19q deletions, differ in the proportion of apoptotic cells but not in replication-licensed non-proliferating cells. Acta Neuropathol 113, 119–127 (2007). https://doi.org/10.1007/s00401-006-0177-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00401-006-0177-2

Keywords

Search

Navigation